SCHEMBL4151090

SCHEMBL4151090

Nc1ccnc2ccc(-c3ccccc3)cc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 4/20 0.60
PIK3CA P42336 4/20 0.59
NCF1 P14598 1/20 0.58
NR4A2 P43354 2/20 0.56
MAPKAPK2 P49137 3/20 0.48
ALK Q9UM73 1/20 0.46
BACE1 P56817 1/20 0.46
JAK2 O60674 1/20 0.45
PLG P00747 1/20 0.44
PLAU P00749 1/20 0.44
DHFR P00374 1/20 0.44
PI4KA P42356 1/20 0.44
PI4KB Q9UBF8 1/20 0.44
MET P08581 1/20 0.43
SOS2 Q07890 1/20 0.43
PIK3CD O00329 1/20 0.43
ABL1 P00519 1/20 0.43
EGFR P00533 1/20 0.43
HCK P08631 1/20 0.43
SRC P12931 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29061683 1.00 MAP4K4 (0.60) MAP4K4PIK3CANCF1NR4A2MAPKAPK2
SCHEMBL15138972 0.86 NCF1 (0.58) MAP4K4PIK3CANCF1NR4A2ALK
SCHEMBL5758549 0.82 NR4A2 (0.56) MAP4K4PIK3CANCF1NR4A2PI4KA
SCHEMBL4146183 0.80 NR4A2 (0.50) MAP4K4PIK3CANCF1NR4A2MAPKAPK2
SCHEMBL4155195 0.80 NR4A2 (0.54) MAP4K4PIK3CANCF1NR4A2MAPKAPK2
SCHEMBL9709110 0.80 PIK3CA (0.87) MAP4K4PIK3CAMAPKAPK2ALKJAK2
SCHEMBL27916529 0.80 SLC22A12 (0.52) MAP4K4NCF1NR4A2MAPKAPK2EGFR
SCHEMBL25402740 0.79 PIK3CA (0.59) MAP4K4PIK3CAMAPKAPK2ALKPLG
SCHEMBL28723682 0.79 PIK3CA (0.59) MAP4K4PIK3CAMAPKAPK2ALKPLG
SCHEMBL31121065 0.79 PIK3CA (0.59) MAP4K4PIK3CAMAPKAPK2ALKPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds DICKSON JR JOHN K 2009-03-12 US disclosed
US-7452887-B2 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AMPHORA DISCOVERY CORPORATION (US) 2008-11-18 US disclosed
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AGRIUS GROUP, LLC. 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds ATP5ME, ABCG2, ATP5MG MAP4K4 1842/4885PIK3CA 1069/4885NCF1 672/4885
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof ATP5ME, ATP5MG, ATP5MK MAP4K4 1968/4885PIK3CA 536/4885NCF1 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.